Chinese Pulmonary Arterial Hypertension Cohort: Selexipag Triple Therapy Outcomes

A retrospective cohort study of 153 Chinese patients with pulmonary arterial hypertension (PAH) treated at Qilu Hospital of Shandong University from February 2022 to November 2023. The dataset likely contains clinical data for safety and efficacy analysis of triple-targeted therapy based on selexipag. It includes non-invasive risk assessment scores, echocardiogram parameters, and clinical outcomes.

Use Cases

• Analyze the impact of initial versus sequential triple therapy on disease progression based on the hazard ratio reported.
• Model improvements in exercise capacity based on the 6-minute walk distance (6MWD) measurements.
• Assess changes in risk stratification based on the count of low-risk criteria reported in the description.
• Evaluate right heart remodeling based on echocardiogram parameters like right atrial area and tricuspid annular plane systolic excursion.

Strengths

• Includes 153 patients for safety analysis and 146 for efficacy analysis.
• Provides a median follow-up period of 29 weeks and an average follow-up of 33 ± 10 months.
• Contains specific outcome metrics including WHO functional class, 6MWD, NT-proBNP levels, and echocardiogram parameters.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect geographic bias inherent to a single-center study in China.

Provenance

Source

figshare, author Xiaopei Cui.

Collection Method

Single-center, retrospective study.

Time Range

Patient data from February 2022 to November 2023.

Freshness

Last updated 2026-05-21 05:44:05; freshness should be verified.

Geography

China, patients from Qilu Hospital of Shandong University.